A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis

Peter C. Taylor; Désirée van der Heijde; Robert Landewé; Shannon McCue; Sue Cheng; Annelies Boonen

doi:10.3899/jrheum.201088

Research ArticleSpondyloarthritis

A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis

Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng and Annelies Boonen

The Journal of Rheumatology August 2021, 48 (8) 1259-1267; DOI: https://doi.org/10.3899/jrheum.201088

Peter C. Taylor

1P.C. Taylor, PhD, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Peter C. Taylor
For correspondence: peter.taylor@kennedy.ox.ac.uk

Désirée van der Heijde

2D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Désirée van der Heijde

Robert Landewé

3R. Landewé, MD, Amsterdam University Medical Center, Amsterdam, and Zuyderland Medical Center, Heerlen, the Netherlands;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Robert Landewé

Shannon McCue

4S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sue Cheng

4S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Annelies Boonen

5A. Boonen, PhD, Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Annelies Boonen

Article
Figures & Data
Supplemental
Info & Metrics
References
PDF

PreviousNext

Data supplements

201088DataSuppl.pdf

PreviousNext

In this issue

The Journal of Rheumatology

Vol. 48, Issue 8

1 Aug 2021

Table of Contents
Table of Contents (PDF)
Index by Author
Editorial Board (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis

Message Subject (Your Name) has forwarded a page to you from The Journal of Rheumatology

Message Body (Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis